Qatar vs Slovenia: HIV/AIDS deaths averted by antiretroviral therapy
Qatar
28.01 deaths
in 2024
Slovenia
36.62 deaths
in 2024
Qatar rank
143rd
Slovenia rank
141st
HIV/AIDS deaths averted by antiretroviral therapy over time
- Qatar
- Slovenia
How they compare
Slovenia currently reports 36.62 deaths against 28.01 deaths in Qatar, a difference of 8.61 deaths.
That makes Slovenia's figure about 1.3 times Qatar's.
Across all 35 years both countries report, Slovenia has been ahead every year.
Qatar ranks 143rd and Slovenia ranks 141st of 157 countries.
Slovenia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Qatar | Slovenia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0.7306 deaths | 0.7306 deaths | Slovenia |
| 2000s | 0.0451 deaths | 10.07 deaths | 10.02 deaths | Slovenia |
| 2010s | 4.48 deaths | 22.1 deaths | 17.62 deaths | Slovenia |
| 2020s | 19.39 deaths | 34.57 deaths | 15.18 deaths | Slovenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Qatar or Slovenia?
- Slovenia, at 36.62 deaths against 28.01 deaths in Qatar as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Qatar and Slovenia?
- 8.61 deaths, with Slovenia ahead.
- How many years of comparable data are there for Qatar and Slovenia?
- 35 years are reported by both, from 1990 to 2024.
- How do Qatar and Slovenia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Qatar ranks 143rd and Slovenia ranks 141st of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.